Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pentoxifylline + valsartan
- Development stage
- Unknown
- Lead developer
- National Taiwan University Hospital
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This combination therapy consists of pentoxifylline, a xanthine derivative, and valsartan, an angiotensin II receptor blocker (ARB). Pentoxifylline is traditionally used to treat peripheral artery disease but possesses significant anti-inflammatory and anti-fibrotic properties, primarily through the inhibition of phosphodiesterases and the downregulation of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha). Valsartan acts as a selective antagonist of the angiotensin II type 1 (AT1) receptor, which helps reduce blood pressure and provides renoprotection by decreasing intraglomerular pressure and proteinuria. The National Taiwan University Hospital has investigated this combination for its potential synergistic renoprotective effects in patients with stage 3 and 4 chronic kidney disease (CKD), aiming to slow the progression to end-stage renal disease (ESRD) and reduce cardiovascular complications.
- Other names
- pentoxifylline and valsartan combinationPTX + ARBpentoxifylline + angiotensin II receptor blocker
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))AGTR1 (Angiotensin II Type-1 receptor)PDE (Phosphodiesterase family)
Beyond the preview
Go deeper on pentoxifylline + valsartan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pentoxifylline + valsartan.